Literature DB >> 31560490

Outcome of 102 patients under 5 years of age with Hodgkin lymphoma.

Asuman N Karhan1, Ali Varan2, Canan Akyüz2, Burça Aydın2, Bilgehan Yalçın2, Tezer Kutluk2, Münevver Büyükpamukçu2.   

Abstract

BACKGROUND: Hodgkin's lymphoma (HL) is one of the most curable pediatric cancers, however it is rare among children under five years of age and prognostic factors for survival rate are still unknown due to low frequency in this age group.
OBJECTIVES: The aim of this study was to evaluate clinical characteristics, treatment regimens, and outcome of patients under five years of age with HL.
METHODS: Patients diagnosed with HL between 1972 and 2013 were retrospectively evaluated. All patients were treated with chemotherapy with or without radiotherapy.
RESULTS: There were 102 patients with a median age of 4 years (range: 2 to 4.9). The median followup time was 13 years. Twenty-three patients had B symptoms, 15 patients had 'bulky disease' and the most common stages were stage I and II. Overall survival (OS) rates were significantly different according to the stage of the cancer (p = 0.008). Although there were no statistically significant differences; the positivity of 'bulky disease' and B symptoms were associated with poor prognosis.
CONCLUSION: Our single-center study included the largest number of patients under five years of age with HL. The stage was the main predictor for OS; on the other hand, the presence of B symptoms and bulky disease has also affected the prognosis. Sociedad Argentina de Pediatría.

Entities:  

Keywords:  Hodgkin's lymphoma; adolescent; child; young adults

Year:  2019        PMID: 31560490     DOI: 10.5546/aap.2019.eng.e459

Source DB:  PubMed          Journal:  Arch Argent Pediatr        ISSN: 0325-0075            Impact factor:   0.635


  1 in total

1.  Impact on the survival of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and monocyte-lymphocyte ratio on prognosis in children with Hodgkin lymphoma.

Authors:  Kubra Ertan; Aysenur Dogru; Buket Kara; Yavuz Koksal
Journal:  Saudi Med J       Date:  2022-05       Impact factor: 1.422

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.